USFDA clears Dr Reddy’s ovarian cancer generic sale

Dr Reddy's Laboratories (DRL) has received approval from the US health regulator to sell its generic version of Alza Corporation's Doxil injection used for treatment of ovarian  cancer.

The approval from the US Food and Drug Administration (USFDA) for doxorubicin hydrochloride liposome intravenous injection is an outcome of extensive collaboration with the company’s partner Natco Pharma on research and development and manufacturing capabilities, Dr Reddy’s said in a BSE filing.
The injection comes in single dose vials of 10 ml or 30 ml, it added.
DRL Executive Vice-President and Head of North American Generics Business Alok Sonig said it is the first of its kind for the company.
“We are preparing for a commercial launch soon,” he added.
The Doxil brand and generic version had sales of about USD 196 million in the 12 months ended March 2017, DRL said citing IMS Health data.
Shares of DRL were trading at Rs 2,743.20 apiece in the afternoon trade, up 0.74 per cent, from the previous close on the BSE.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Merck announces positive event-free survival data from phase 3 KEYNOTE-522 study of Keytruda to treat triple-negative breast cancer